Product data
- Strength
- 2.5 mg, 5 mg
- Dosage form
- Tablet
- Dosage-form group
- Oral solid
- Therapeutic area
- Anticoagulant
- Market
- EU/US
- Status
- Dossier target · Jun 2027
- Development status
- Pilot bio planned Oct 2026
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23